前列腺癌骨转移机制和骨靶向药物研究进展  

Research progression in the mechanism of bone metastasis and bone-targeted drugs in prostate cancer

作　　者：韩焱崧(综述) 任明华(审校)[1] HAN Yansong;REN Minghua(Department of Urology,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院泌尿外科,哈尔滨150001

出　　处：《实用肿瘤学杂志》2023年第3期252-256,共5页Practical Oncology Journal

基　　金：黑龙江省自然科学基金(编号:LH2019H030)。

摘　　要：骨是前列腺癌最常见的晚期转移部位,骨微环境和前列腺癌中多种细胞因子如核因子-κB受体活化因子配体(Receptor activator of NF-κB ligand, RANKL)、趋化因子家族、整合素等通过复杂的相互作用机制参与了前列腺癌骨转移。多种骨靶向药物如二磷酸盐、地诺单抗和放疗药物如镭-223被批准用于预防和治疗因前列腺癌骨转移引起的骨骼相关事件(Skeletal-related events, SREs)。本文对前列腺癌骨转移的生物学机制和骨靶向药物研究进展进行综述。Bone is the most common metastatic site of advanced prostate cancer(PCa).Various cytokines such as receptor activator of nuclear factor-κB ligand(RANKL),chemokine families,integrins,etc.in the bone microenvironment and PCa,are involved in bone metastasis of PCa through complex interaction mechanisms.Multiple bone-targeted drugs such as disphosphonate,denosumab,and radiotherapy drugs such as radium-223 have been approved for prevention and treatment of skeletal related events(SREs)caused by PCa bone metastases.This article reviews the biological mechanisms of prostate cancer bone metastasis and the research progression of bone-targeted drugs.

关 键 词：前列腺癌 骨转移机制 骨靶向药物 

分 类 号：R737.25[医药卫生—肿瘤]